BD (Becton, Dickinson and Company) announced the launch of the BD UltraSafe Plus 2.25 mL Passive Needle Guard for use by pharmaceutical companies in drug-device combination products. When combined with a Glass Prefillable Syringe, the BD UltraSafe Plus 2.25 mL system enables the subcutaneous delivery of biologic solutions of different fill volumes up to 2 mL and viscosities up to 30 cP, according to a press release from the company.
BD UltraSafe Plus 2.25 mL is the latest solution to be commercially released into BD’s portfolio of drug delivery systems for combination products and is designed to meet the needs of healthcare providers, patients, and caregivers in performing manual injections of biologic solutions. The unique design of BD UltraSafe Plus 2.25 mL complements bio-pharmaceutical companies’ combination product strategies – enabling patient-controlled injection for complex, high-viscosity drugs.
Biologic therapies are often self-administered by patients or caregivers and require delivery systems that provide ease of use and safety benefits for use in non-clinical settings. However, the viscosity and injection volume of biologics has shown a tendency to increase over the last years (>1 mL, >10 cP) that are beyond the capabilities of many commercialized injectable drug delivery systems. Biologic formulations with high volumes and viscosities often require stronger forces to inject, which can create challenges from a user’s perspective.